Who are Experimental: SNF472's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AMG 073.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/experimental-snf472.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Experimental: SNF472 — Competitive Intelligence Brief

Experimental: SNF472 (Experimental: SNF472) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcimimetic agent. Area: Nephrology / Cardiovascular.

phase 3 Calcimimetic agent Calcium-sensing receptor (CaSR) Nephrology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Experimental: SNF472 (Experimental: SNF472) — Sanifit Therapeutics S. A.. SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Experimental: SNF472 TARGET	Experimental: SNF472	Sanifit Therapeutics S. A.	phase 3	Calcimimetic agent	Calcium-sensing receptor (CaSR)
AMG 073	AMG 073	Amgen	marketed	Calcimimetic agent	Calcium-sensing receptor (CaSR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcimimetic agent class)

Amgen · 1 drug in this class
Multitude Therapeutics Inc. · 1 drug in this class
Sanifit Therapeutics S. A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Experimental: SNF472 — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-snf472. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab